PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1557506

Beta-phenylethylamine and noradrenergic function in depression.

M Nakagawara
View original source ↗Export metadata ↓

Abstract

1. The relationship between plasma levels of beta-phenylethylamine (PEA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) was investigated in depressive patients. 2. The mean PEA level in plasma in healthy subjects was 1.19 ng/ml (N = 32). No clearly age-related difference was found. The plasma levels of PEA were measured in major depression, but no significant difference was found between healthy and depressive subjects. 3. Plasma levels of MHPG correlated positively with age in healthy subjects (N = 22, R = 0.71, p less than 0.01). There was no significant difference in MHPG levels between healthy subjects and depressive patients. 4. There was no significant correlation between PEA and MHPG levels in healthy subjects; however, in depressive patients, there was a significant negative correlation between plasma PEA levels and plasma MHPG levels (N = 14, R = -0.73, p less than 0.05). These results suggested that PEA may regulate noradrenergic function in depression.

Explore related subjects

Depressive DisorderFemaleHumansMaleMethoxyhydroxyphenylglycolNorepinephrinePhenethylaminesPhenylethanolamine N-MethyltransferaseJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Nakagawara. 1992. Beta-phenylethylamine and noradrenergic function in depression.. https://doi.org/10.1016/0278-5846(92)90007-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Psychological morbidity and female urinary incontinence.

Female urinary incontinence is a common yet distressing condition. It affects women of all ages, but is especially common in the elderly. Its prevalence ranges from 15 to 55%, depending on age and population studied. Despite the ubiquity of female urinary incontinence, many incontinent women do not voice their suffering, and urinary incontinence has therefore been dubbed 'the silent epidemic'. The physical impact and social isolation associated with urinary incontinence lead to impairment of quality of life and psychological well-being. It is the aim of this review to discuss the epidemiology and psychological impact of urinary incontinence. The recognition and management of incontinence-related psychological morbidity are also explored.

Depressive Disorder↗
PubMed2007

Vagus nerve stimulation therapy in depression and epilepsy: therapeutic parameter settings.

Vagus nerve stimulation (VNS) therapy is an effective adjunctive treatment for chronic or recurrent treatment-resistant depression in adults, and for pharmacoresistant epilepsy in adults and adolescents. VNS therapy is administered through an implanted pulse generator that delivers programmed electrical pulses through an implanted lead to the left vagus nerve. Programmable pulse parameters include output current, frequency, pulse width, and ON/OFF times. Within a range of typical values, individual patients respond best to different combinations of parameter settings. The physician must identify the optimum settings for each patient while balancing the goals of maximizing efficacy, minimizing side effects, and preserving battery life. Output current is gradually increased from 0.25 mA to the maximum tolerable level (maximum, 3.5 mA); typical therapeutic settings range from 1.0 to 1.5 mA. Greater output current is associated with increased side effects, including voice alteration, cough, a feeling of throat tightening, and dyspnea. Frequency is typically programmed at 20 Hz in depression and 30 Hz in epilepsy. Pulse width is typically 250 or 500 micros. The recommended initial ON time is 30 s, followed by 5 min OFF; OFF time > ON time is recommended. As with pharmacotherapy, VNS therapy must be adjusted in a gradual, systematic fashion to individualize therapy for each patient.

Depressive Disorder↗